Cargando…

Efficacy and safety of NOAC versus warfarin in AF patients with left atrial enlargement

BACKGROUND: Little is known about the effects of anticoagulation in patients with atrial fibrillation (AF) and left atrial enlargement (LAE). METHODS: Data of patients with AF were retrieved from Chang Gung Research Database during 2007–2016. We excluded patients who were not using oral anticoagulan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Victor Chien-Chia, Wang, Chun-Li, Gan, Shu-Ting, Wu, Michael, Chen, Shao-Wei, Kuo, Chang-Fu, Huang, Yu-Tung, Wen, Ming-Shien, Chang, Shang-Hung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7735599/ https://www.ncbi.nlm.nih.gov/pubmed/33315930 http://dx.doi.org/10.1371/journal.pone.0243866

Ejemplares similares

Novel oral anticoagulant vs. warfarin in elderly atrial fibrillation patients with normal, mid‐range, and reduced left ventricular ejection fraction
por: Wu, Victor Chien‐Chia, et al.
Publicado: (2020)

NOACs vs. Warfarin for Stroke Prevention in Nonvalvular Atrial Fibrillation
por: Patel, Priya, et al.
Publicado: (2017)

Real-World Comparisons of Low-Dose NOACs versus Standard-Dose NOACs or Warfarin on Efficacy and Safety in Patients with AF: A Meta-Analysis
por: Li, Ze, et al.
Publicado: (2022)

NOACs versus warfarin for stroke prevention in patients with AF: a systematic review and meta-analysis
por: Hicks, Tim, et al.
Publicado: (2016)

Novel Oral Anticoagulant versus Warfarin in Cancer Patients with Atrial Fibrillation: An 8-Year Population-Based Cohort Study
por: Wu, Victor Chien-Chia, et al.
Publicado: (2020)

Effectiveness and Safety of NOAC Versus Warfarin in Patients With Atrial Fibrillation and Aortic Stenosis
por: Melgaard, Line, et al.
Publicado: (2021)

Long-Term Persistence with Newly-Initiated Warfarin or Non-VKA Oral Anticoagulant (NOAC) in Patients with Non-Valvular Atrial Fibrillation: Insights from the Prospective China-AF Registry
por: Liu, Chang, et al.
Publicado: (2019)

Safety and Effectiveness of Direct Oral Anticoagulants vs. Warfarin in Patients With Atrial Fibrillation and Endoscopy-Diagnosed Peptic Ulcer
por: Wang, Chun-Li, et al.
Publicado: (2021)

A prospective survey of the persistence of warfarin or NOAC in nonvalvular atrial fibrillation: a COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation (CODE-AF)
por: Kim, Hyeongsoo, et al.
Publicado: (2020)

Comparing clinical outcomes of NOACs with warfarin on atrial fibrillation with Valvular heart diseases: a meta-analysis
por: He, Qiyu, et al.
Publicado: (2019)

Low-Dose NOACs Versus Standard-Dose NOACs or Warfarin on Efficacy and Safety in Asian Patients with NVAF: A Meta-Analysis
por: Li, Ze, et al.
Publicado: (2022)

Intraocular Bleeding in Patients With Atrial Fibrillation Treated With NOACs VS. Warfarin: A Systematic Review and Meta-Analysis
por: Liu, Fuwei, et al.
Publicado: (2022)

NOAC versus warfarin in the treatment of atrial fibrillation during the first three months after bioprosthetic aortic valve replacement
por: Piepiorka-Broniecka, Marta, et al.
Publicado: (2022)

Do Patients with Atrial Fibrillation and a History of Ischemic Stroke Overuse Reduced Doses of NOACs?—Results of the Polish Atrial Fibrillation (POL-AF) Registry
por: Szyszkowska, Anna, et al.
Publicado: (2022)

Safety and Effectiveness of Non–Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation and Anemia: A Retrospective Cohort Study
por: Wang, Chun‐Li, et al.
Publicado: (2019)

Erratum to: NOACs for secondary stroke prevention in patients with atrial fibrillation
Publicado: (2020)

Antithrombotic management and outcomes of patients with atrial fibrillation treated with NOACs early at the time of market introduction: Main results from the PREFER in AF Prolongation Registry
por: Renda, Giulia, et al.
Publicado: (2020)

Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation
por: Chan, Yi‐Hsin, et al.
Publicado: (2018)

Lack of reversibility for NOACs
por: Al-Kindi, Sadeer
Publicado: (2014)

TAVR: nemesis of NOACs?
por: Polzin, Amin, et al.
Publicado: (2022)

Effectiveness and Safety of Non–Vitamin K Antagonist Oral Anticoagulant and Warfarin in Cirrhotic Patients With Nonvalvular Atrial Fibrillation
por: Lee, Hsin‐Fu, et al.
Publicado: (2019)

Net Clinical Benefit of Left Atrial Appendage Closure Versus Warfarin in Patients With Atrial Fibrillation: A Pooled Analysis of the Randomized PROTECT‐AF and PREVAIL Studies
por: Brouwer, Tom F., et al.
Publicado: (2019)

Is Initiating NOACs for Atrial Arrhythmias Safe in Adults with Congenital Heart Disease?
por: Yang, Hayang, et al.
Publicado: (2017)

Efficacy and Safety of Non–Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients With Impaired Liver Function: A Retrospective Cohort Study
por: Wang, Chun‐Li, et al.
Publicado: (2018)

Cardiovascular outcomes in patients with atrial fibrillation concomitantly treated with antiarrhythmic drugs and non-vitamin k antagonist oral anticoagulants
por: Wu, Victor Chien-Chia, et al.
Publicado: (2023)

Nocturia independently predicts left ventricular hypertrophy and left atrial enlargement among patients with cardiac symptoms
por: Kao, Kuo-Wei, et al.
Publicado: (2022)

Warfarin slows deterioration of renal function in elderly patients with chronic kidney disease and atrial fibrillation
por: Chang, Chia-Chu, et al.
Publicado: (2013)

The Patterns of Non-vitamin K Antagonist Oral Anticoagulants (NOACs) Use in Patients with Atrial Fibrillation in Seven Balkan Countries: a Report from the BALKAN-AF Survey
por: Potpara, Tatjana S., et al.
Publicado: (2017)

The association between hyperuricemia and left atrial enlargement in healthy adults
por: Fang, Danhong, et al.
Publicado: (2021)

Management and outcomes of real-world use of non-vitamin-K oral anticoagulants (NOACs) in patients with atrial fibrillation: experience of a dedicated NOAC clinic
por: de Veer, A. J. W. M., et al.
Publicado: (2019)

Comparisons of Rivaroxaban Following Different Dosage Criteria (ROCKET AF or J‐ROCKET AF Trials) in Asian Patients With Atrial Fibrillation
por: Chan, Yi‐Hsin, et al.
Publicado: (2019)

Response to ‘Lack of reversibility for NOACs’
por: Kaba, Riyaz A, et al.
Publicado: (2014)

Bleeding risk with dabigatran, rivaroxaban, warfarin, and antiplatelet agent in Asians with non-valvular atrial fibrillation
por: Chan, Yi-Hsin, et al.
Publicado: (2017)

New score for assessing bleeding risk in patients with atrial fibrillation treated with NOACs
por: Rutherford, Ole-Christian Walter, et al.
Publicado: (2018)

Baseline characteristics and event rates among anticoagulated patients with atrial fibrillation in practice and pivotal NOAC trials
por: Noseworthy, Peter A., et al.
Publicado: (2017)

Do NOACs Improve Antithrombotic Therapy in Secondary Stroke Prevention in Nonvalvular Atrial Fibrillation?
por: Lin, Yi-Pin, et al.
Publicado: (2015)

Correction: New score for assessing bleeding risk in patients with atrial fibrillation treated with NOACs
Publicado: (2020)

Protecting against sedentary lifestyle, left atrial enlargement and atrial fibrillation
por: Sanchis-Gomar, Fabian, et al.
Publicado: (2022)

Clinical impact of left atrial enlargement in Korean patients with atrial fibrillation
por: Cho, Min Soo, et al.
Publicado: (2021)

The reliability of chest radiographs in predicting left atrial enlargement
por: Quinton, SJ, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_ltdl4gufrqhbfph4vo4thi9h8f